Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Precise, pragmatic and inclusive: the modern era of oncology clinical trials

Nature Medicine volume 29, pages 1908–1909 (2023)Cite this article

Subjects

Innovative clinical trial designs with a patient-centered mission are crucial to advancing modern cancer care; the adaptive phase 2 umbrella study CTONG1702 provides one model for this new era of trial design.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Increasing patient engagement in precision oncology clinical trials.

References

  1. Riudavets, M., Sullivan, I., Abdayem, P. & Planchard, D. ESMO Open 6, 100260 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Li, B. T. et al. N. Engl. J. Med. 386, 241–251 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. Subbiah, V. Nat. Med. 29, 49–58 (2023).

    Article  CAS  PubMed  Google Scholar 

  4. Liu, S. Y. M. T. H. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02461-x (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Redman, M. W. et al. Lancet Oncol. 21, 1589–1601 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kim, E. S. et al. Clin. Cancer Res. 27, 2394–2399 (2021).

    Article  PubMed  Google Scholar 

  7. Cancer Discov. 13, 1279–1280 (2023).

  8. Nabhan, C., Klink, A. & Prasad, V. JAMA Oncol. 5, 781–783 (2019).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA

    Michael J. Grant & Sarah B. Goldberg

Authors
  1. Michael J. Grant
    View author publications

    Search author on:PubMed Google Scholar

  2. Sarah B. Goldberg
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Sarah B. Goldberg.

Ethics declarations

Competing interests

S.B.G. reports research funding from AstraZeneca, Boehringer Ingelheim and Mirati, and consulting for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Amgen, Blueprint Medicine, Sanofi Genzyme, Daiichi-Sankyo, Takeda, Janssen, Summit Therapeutics, Merck and Regeneron. M.J.G. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grant, M.J., Goldberg, S.B. Precise, pragmatic and inclusive: the modern era of oncology clinical trials. Nat Med 29, 1908–1909 (2023). https://doi.org/10.1038/s41591-023-02466-6

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41591-023-02466-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer